Welcome to our dedicated page for Corvus Pharmaceuticals SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corvus Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corvus Pharmaceuticals's regulatory disclosures and financial reporting.
Corvus Pharmaceuticals, Inc. reported that director Ian T. Clark delivered notice on July 21, 2026 of his intention to resign from the company’s board of directors, effective July 22, 2026. The company acknowledged and thanked Mr. Clark for his significant contributions during over nine years of board service.
Corvus Pharmaceuticals director David Scott Moore reported buying shares and receiving stock options. He completed an open-market purchase of 21,700 shares of Common Stock at an average price of $11.5316 per share, and now holds 21,700 common shares directly.
He was also granted a stock option for 15,000 shares of Common Stock at an exercise price of $11.60 per share. The option vests in full on the earlier of the first anniversary of the grant date or the date of Corvus Pharmaceuticals’ 2027 Annual Meeting of stockholders, assuming continuous service as a director until that vesting date.
Corvus Pharmaceuticals director Ian T. Clark received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on June 11, 2036, representing compensation rather than an open-market purchase.
The underlying shares vest and become exercisable in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director through that date. After this grant, Clark holds stock options for 15,000 shares from this award.
Corvus Pharmaceuticals director Linda Grais received a grant of stock options as equity compensation. The Form 4 shows an award of 15,000 options to buy Common Stock at an exercise price of $11.6000 per share, expiring on June 11, 2036.
The underlying 15,000 shares vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of stockholders, assuming she continues to serve as a director through that vesting date.
Corvus Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $11.6000 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or the date of Corvus’ 2027 annual stockholders’ meeting, assuming continuous board service through that date. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, any securities or economic benefits from these options are to be provided to OrbiMed Private Investments V, LP, and Thompson disclaims beneficial ownership except to any pecuniary interest.
Corvus Pharmaceuticals director Richard van den Broek received a new stock option grant. On the reported date, he was awarded options to buy 15,000 shares of Corvus common stock at an exercise price of $11.60 per share. All 15,000 options vest in a single tranche on the earlier of the first anniversary of the grant or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director until that vesting date.
Corvus Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where stockholders voted on director elections, auditor ratification, and executive compensation.
Two Class I directors, Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, on a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers. A total of 73,021,854 shares of common stock were voted out of 84,090,424 shares outstanding as of the April 16, 2026 record date.
Corvus Pharmaceuticals, Inc. President and CEO Dr. Richard A. Miller reported additional open-market purchases of the company’s common stock. Through the Miller-Horning Family Trust, where he shares voting and investment power, the trust bought 1,932 shares at $12.01 per share and 5,000 shares at $12.05 per share on May 18, 2026, totaling 6,932 shares. After these transactions, he reports 1,136,707 shares held directly and 1,195,035 shares held indirectly through the trust.
Corvus Pharmaceuticals, Inc. Amendment No. 1 to a Schedule 13G/A reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen held 0% of the company's common stock as of the close of business on 03/31/2026. The cover page entries show zero voting and dispositive power for the reporting persons on that date.
Corvus Pharmaceuticals Schedule 13G: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 6,831,828 shares of Common Stock issuable upon exercise of warrants, representing 7.5% of the class. This percentage is calculated using March 12, 2026 outstanding shares of 83,992,407 and assumes exercise of the warrants.
The filing states the shared voting and dispositive power over the 6,831,828 warrant-issuable shares and attaches a Joint Filing Agreement as Exhibit 99.1.